The FDA's Schedule I label on cannabis is the single biggest barrier holding medical marijuana stocks back.
That barrier could be coming down soon, and you'll want to own shares of GW Pharmaceuticals when it does.
Lo and behold – a bill is moving through the U.S.
Senate to do just this.
by Don Yocham
Start the conversation
Leave a Reply Click here to cancel reply.
You must be logged in to post a comment.
Some market-leading biotech firms are working hard right now developing drugs derived from cannabis' many beneficial compounds.
And there's one innovative company that puts you right in the middle of the sector's market-crushing gains.
Plus, there's still some time left to get in and grab the profits….
Start the conversation
Leave a Reply Click here to cancel reply.
You must be logged in to post a comment.
By 2025, the biotech industry will be worth will be $727 billion – a 120% increase over its total value in 2015.
To help you take advantage of the tremendous gains in biotech stocks, we're bringing you the three best biotech stocks to buy this month.
Start the conversation
Leave a Reply Click here to cancel reply.
You must be logged in to post a comment.
Since hitting a high in late January, the iShares Nasdaq Biotechnology ETF has slumped more than 11%. But that doesn't mean investors should stop looking for the best biotech stocks to buy today.
You see, the slump in biotech stocks has little to do with their true worth.
In fact, some of the best biotech stocks are currently trading well below their fundamental value, according to their earnings and assets.
Here are the three best biotech stocks to buy now, while they're still on sale...
by Stephen Mack
Start the conversation
Leave a Reply Click here to cancel reply.
You must be logged in to post a comment.
Biotech stocks have been getting hit hard in early 2018, but it's largely because of market overreactions to minor setbacks and rumors.
Based on earnings and assets, some biotech stocks are now available at remarkable discounts.
We've got three picks that are ready to break out in a big way.
by Stephen Mack
Start the conversation
Leave a Reply Click here to cancel reply.
You must be logged in to post a comment.
Our latest round of stocks to buy now is heavy on tech.
These stocks capitalize on legal marijuana, tailwinds in the biotech industry, a race to build a supercomputer, and the urbanization of the tech industry.
Don't miss out on these gains.
Start the conversation
Leave a Reply Click here to cancel reply.
You must be logged in to post a comment.
Back in October, I did something crazy.
That's when I told the paid-up members of my Radical Technology Profits trading service to buy a small-cap biotech stock.
Here's why that move was a bit nuts.
At the time, it looked like Hillary Clinton would soon enter in the White House and clamp down on drug prices – and so the biopharmaceutical sector was deeply out of favor.
Turns out, however, our crazy bet paid off.
Despite his campaign rhetoric, President Donald Trump has pulled back from his own fiery rhetoric about drug-price caps.
That helped pushed biotech and drug stocks into a big uptrend.
And my paid-up members made peak gains of 116% – in just over eight months.
Today, things have changed – and investing in biopharma stocks is generally seen as a smart move. However, that means a lot of these shares have been bid up, and your best move is to buy big winners at deep discounts.
But to do that, you have to know how to find those deals.
I do.
Today I'll show you how you can, too.
And I'll reveal the three best biotech bargains out there right now.
All three have triple-digit gains potential...
Start the conversation
Leave a Reply Click here to cancel reply.
You must be logged in to post a comment.
Another possible deal between two of the world's top pharmaceutical companies was announced this week when Shire Plc. (Nasdaq: SHPG) made an unsolicited offer of $30.6 billion for Baxalta Inc. (NYSE: BXLT).
Money Morning Defense & Tech Specialist Michael A. Robinson has been following this trend since 2014. He knew the world's top pharmaceutical companies would continue their M&A binge, and he recommended an investment to play that wave.
Robinson's pick has already climbed 17.6% this year and still has plenty of room to run...
Start the conversation